
- /
- Supported exchanges
- / US
- / CPRX.NASDAQ
Catalyst Pharmaceuticals Inc (CPRX NASDAQ) stock market data APIs
Catalyst Pharmaceuticals Inc Financial Data Overview
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Catalyst Pharmaceuticals Inc data using free add-ons & libraries
Get Catalyst Pharmaceuticals Inc Fundamental Data
Catalyst Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 535 M
- EBITDA: 269 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: 0.5267
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Catalyst Pharmaceuticals Inc News

Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looki...


Catalyst (CPRX) Loses 12.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Catalyst Pharmaceutical (CPRX) has been beaten down lately with too much selling pressure. While the stock has lost 12.2% over the past four weeks, there is light at the end of the tunnel as it is now...

CPRX vs. NBIX: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors...

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Many investors also have a go-to methodology that...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.